In Brief: Kensey Nash
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash: Relaunches 8F Angio-Seal in the European marketplace following a lapse of availability for several months "due to the interruption of production caused by damage from a roof collapse sustained at Kensey Nash's facility during a January snowstorm," the firm says. Angio-Seal, which is designed to seal arterial punctures following cardiac catheterization procedures, gained the CE Mark in September 1995. Kensey Nash received an FDA approvable letter for the device in July 1995...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.